ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results